Brain in flames – Animal models of psychosis: Utility and limitations

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 1313-1329

  Mattei, Daniele ^a   Schweibold, Regina ^a,b   Wolf, Susanne A ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HELIOS Clinic   (Germany)

Author keywords

Animal models; Inflammation; Microglia; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DIZOCILPINE; HALOPERIDOL; IBOTENIC ACID; KETAMINE; LIPOPOLYSACCHARIDE; MINOCYCLINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; POLYCYTIDYLIC ACID; TETRODOTOXIN;

ANIMAL MODEL; COGNITIVE DEFECT; CYTOKINE RELEASE; DEVELOPMENTAL MODEL; DISEASE MODEL; EXCITOTOXICITY; GABAERGIC SYSTEM; GENETIC MODEL; HUMAN; MATERNAL IMMUNE ACTIVATION MODEL; MICROGLIA; NEGATIVE SYNDROME; NEONATAL VENTRAL HIPPOCAMPAL LESION MODEL; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NONHUMAN; PHARMACOLOGICAL MODEL; POSITIVE SYNDROME; PREFRONTAL CORTEX; PRENATAL EXPOSURE; PREPULSE INHIBITION; REVIEW; SCHIZOPHRENIA; TRANSGENIC MOUSE; VENTRAL HIPPOCAMPUS;

EID: 84933499356     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S65564     Document Type: Review

References (193)

1. Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci. 2010;64(3):217-230. doi:10.1111/j.1440-1819.2010.02094.x.
2. Horváth S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry. 2014;75(4):316-323. doi:10.1016/j.biopsych. 2013.06.010.
3. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222.
4. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647. doi:10.1001/archpsyc.64.6.633.
5. Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology. 2011;36(1):316-338. doi:10.1038/npp.2010.156.
6. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand. 2007;115(2):93-100. doi:10.1111/j.1600-0447.2007.00992.x.
7. Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1):58-62.
8. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622.
9. Pakpoor J, Agius M. A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatr Danub. 2014;26(Suppl 1):273-284.
10. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26(9):1185-1193. doi:10.1177/ 0269881112444941.
11. Jhamnani K, Shivakumar V, Kalmady S, Rao NP, Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci. 2013;25(1):E06-E07. doi:10.1176/appi.neuropsych.11120376.
12. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138-149. doi:10.4088/JCP.08m04666yel.
13. Frick LR, Williams K, Pittenger C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol. 2013;2013:608654. doi:10.1155/ 2013/608654.
14. Bernstein H-G, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res. 2015;161(1):4-18. doi:10.1016/j.schres.2014.03.035.
15. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50(11):1801-1807. doi:10.2967/jnumed.109.066647.
16. Van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64(9):820-822. doi:10.1016/j.biopsych.2008.04.025.
17. Zhu F, Liu Y, Zhao J, Zheng Y. Minocycline alleviates behavioral deficits and inhibits microglial activation induced by intrahippocampal administration of Granulocyte-Macrophage Colony-Stimulating Factor in adult rats. Neuroscience. 2014;266:275-281. doi:10.1016/j.neuroscience.2014.01.021.
18. Juckel G, Manitz MP, Brüne M, Friebe A, Heneka MT, Wolf RJ. Microglial activation in a neuroinflammational animal model of schizophrenia-a pilot study. Schizophr Res. 2011;131(1-3):96-100. doi:10.1016/j.schres.2011.06.018.
19. Mattei D, Djodari-Irani A, Hadar R, et al. Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behav Immun. 2014;38:175-184. doi:10.1016/j.bbi.2014.01.019.
20. Zhang L, Zhao J. Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1103-1111. doi:10.2147/NDT.S64236.
21. González JC, Egea J, Del Carmen Godino M, et al. Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca2+ signalling in hippocampal neurons. Eur J Neurosci. 2007;26(9):2481-2495. doi:10.1111/j.1460-9568.2007.05873.x.
22. Willner P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(6):677-690.
23. Smith CL, Bolton A, Nguyen G. Genomic and epigenomic instability, fragile sites, schizophrenia and autism. Curr Genomics. 2010;11(6): 447-469. doi:10.2174/138920210793176001.
24. Network P. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18(2):199-209. doi:10.1038/nn.3922.
25. Van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull. 2008;34(6):1066-1082. doi:10.1093/schbul/sbn117.
26. Miyamoto Y, Nitta A. Behavioral phenotypes for negative symptoms in animal models of schizophrenia. J Pharmacol Sci. 2014;126(4):310-320. doi:10.1254/jphs.14R02CR.
27. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull. 2010;36(2):246-270. doi:10.1093/schbul/sbp132.
28. Krueger D, Howell J, Hebert B, Olausson P, Taylor J, Nairn A. Assessment of cognitive function in the heterozygous reeler mouse. Psychopharmacology (Berl). 2006;189(1):95-104. doi:10.1007/s00213-006-0530-0.
29. Seshadri S, Kamiya A, Yokota Y, et al. Disrupted-in-schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc Natl Acad Sci U S A. 2010; 107(12): 5622-5627. doi:10.1073/pnas.0909284107.
30. Jaaro-Peled H, Ayhan Y, Pletnikov MV, Sawa A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr Bull. 2010;36(2):301-313. doi:10.1093/schbul/sbp133.
31. Harvey L, Boksa P. A stereological comparison of GAD67 and reelin expression in the hippocampal stratum oriens of offspring from two mouse models of maternal inflammation during pregnancy. Neuropharmacology. 2012;62(4):1767-1776. doi:10.1016/j.neuropharm. 2011.11.022.
32. Ratnayake U, Quinn TA, Castillo-Melendez M, Dickinson H, Walker DW. Behaviour and hippocampus-specific changes in spiny mouse neonates after treatment of the mother with the viral-mimetic Poly I:C at mid-pregnancy. Brain Behav Immun. 2012;26(8):1288-1299. doi:10.1016/j.bbi.2012.08.011.
33. Tang B, Jia H, Kast RJ, Thomas EA. Epigenetic changes at gene promoters in response to immune activation in utero. Brain Behav Immun. 2013;30(2):168-175. doi:10.1016/j.bbi.2013.01.086.
34. Marsman A, Van Den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull. 2013;39(1):120-129. doi:10.1093/schbul/sbr069.
35. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27(43):11496-11500. doi:10.1523/JNEUROSCI.2213-07.2007.
36. Anticevic A, Corlett PR, Cole MW, et al. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol Psychiatry. 2015;77(6):569-580. doi:10.1016/j.biopsych.2014.07.022.
37. Bondi C, Matthews M, Moghaddam B. Glutamatergic animal models of schizophrenia. Curr Pharm Des. 2012;18(12):1593-1604.
38. Moghaddam B, Jackson ME. Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci. 2003;1003(1):131-137. doi:10.1196/annals. 1300.065.
39. Hou Y, Zhang H, Xie G, et al. Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:107-116. doi:10.1016/j.pnpbp.2013.04.006.
40. Monte AS, de Souza GC, McIntyre RS, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol. 2013;27(11):1032-1043. doi:10.1177/0269881113503506.
41. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):687-700. doi:10.1016/S0278-5846(03)00080-0.
42. Silvestre JS, Nadal R, Pallarés M, Ferré N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety. 1997;5(1):29-33. doi:10.1002/(SICI)1520-6394(1997)5:1<29::AID-DA5>3.0.CO;2-0.
43. Chindo BA, Adzu B, Yahaya TA, Gamaniel KS. Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(2):310-316. doi:10.1016/j.pnpbp.2012.04.018.
44. Zhu S, Wang H, Shi R, et al. Chronic phencyclidine induces inflammatory responses and activates GSK3β in mice. Neurochem Res. 2014;39(12):2385-2393. doi:10.1007/s11064-014-1441-9.
45. Nakki R, Nickolenko J, Chang J, Sagar SM, Sharp FR. Haloperidol prevents ketamine-and phencyclidine-induced hsp70 protein expression but not microglial activation. Exp Neurol. 1996;137(2):234-241.
46. Noda Y, Yamada K, Furukawa H, Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol. 1995;116:2531-2537.
47. Schroeder U, Schroeder H, Schwegler H, Sabel BA. Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. Br J Pharmacol. 2000;130:33-40. doi:10.1038/sj.bjp.0703171.
48. Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):336-339. doi:10.1016/j.pnpbp.2007.08.031.
49. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol. 1996;7(1):3-23.
50. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol. 1997;8(2-3):196-215.
51. Noda A, Noda Y, Kamei H, et al. Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma1 receptors. Neuropsychopharmacology. 2001;24(4):451-460. doi:10.1016/S0893-133X(00)00192-5.
52. Fellini L, Kumar G, Gibbs S, Steckler T, Talpos J. Re-evaluating the PCP challenge as a pre-clinical model of impaired cognitive flexibility in schizophrenia. Eur Neuropsychopharmacol. 2014;24(11):1836-1849. doi:10.1016/j.euroneuro.2014.08.012.
53. Brown JW, Rueter LE, Zhang M. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog Neuropsychopharmacol Biol Psychiatry. 2014;49:53-62. doi:10.1016/j.pnpbp.2013.11.008.
54. Gaisler-Salomon I, Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berl). 2003;166(4):333-342. doi:10.1007/s00213-002-1311-z.
55. Rung JP, Carlsson A, Ryden Markinhuhta K, Carlsson ML. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(5):827-832. doi:10.1016/j.pnpbp.2005.03.004.
56. Rung JP, Carlsson A, Markinhuhta KR, Carlsson ML. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):833-839. doi:10.1016/j.pnpbp.2005.03.003.
57. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition de fi cits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25(3):356-364. doi:10.1016/j.euroneuro.2014.12.014.
58. Levin ED, Bettegowda C, Weaver T, Christopher NC. Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav. 1998;61(3):335-340. doi:10.1016/S0091-3057(98)00109-9.
59. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008;32(5):1014-1023. doi:10.1016/ j.neubiorev.2008.03.012.
60. Horvath ZC, Czopf J, Buzsaki G. MK-801-induced neuronal damage in rats. Brain Res. 1997;753(2):181-195.
61. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007;1154:154-162. doi:10.1016/j.brainres. 2007.03.080.
62. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94:819-827. doi:10.1111/j.1471-4159.2005. 03219.x.
63. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J Biol Chem. 2007;282(20):15208-15216. doi:10.1074/jbc.M611907200.
64. Kobayashi K, Imagama S, Ohgomori T, et al. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis. 2013;4(3):e525. doi:10.1038/cddis.2013.54.
65. Fix AS, Horn JW, Wightman KA, et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol. 1993;123:204-215. doi:10.1006/exnr.1993.1153.
66. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007;32(9):2004-2010. doi:10.1038/sj.npp.1301313.
67. Zhang XY, Chen D-C, Tan Y-L, et al. The interplay between BDNF and oxidative stress in chronic schizophrenia. Psychoneuroendocrinology. 2015;51:201-208. doi:10.1016/j.psyneuen.2014.09.029.
68. Boskovic M, Vovk T, Kores Plesnicar B, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol. 2011;9(2):301-312. doi:10.2174/157015911795596595.
69. Lipska BK, Halim ND, Segal PN, Weinberger DR. Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat. J Neurosci. 2002;22(7):2835-2842. doi: 20026195.
70. Lipska BK, Jaskiw GE, Chrapusta S, Karoum F, Weinberger DR. Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res. 1992;585(1-2):1-6. doi:10.1016/0006-8993(92)91184-G.
71. Lipska BK, Weinberger DR. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox Res. 2002;4(5-6):469-475. doi:10.1080/1029842021000022089.
72. Tseng K-Y, Lewis BL, Lipska BK, O'Donnell P. Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. Biol Psychiatry. 2007;62(7):730-738. doi:10.1016/j.biopsych.2006.10.012.
73. Feleder C, Tseng KY, Calhoon GG, O'Donnell P. Neonatal intrahippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats. Biol Psychiatry. 2010;67(4):386-392. doi:10.1016/j.biopsych.2009.09.028.
74. Lipska B, Weinberger D. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox Res. 2002;4(5-6):469-475. doi:10.1080/1029842021000022089.
75. Tseng KY, O'Donnell P. Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cereb Cortex. 2007; 17(5):1235-1240. doi:10.1093/cercor/bhl034.
76. Weinberger DR, Lipska BK. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res. 1995;16:87-110. doi:10.1016/0920-9964(95)00013-C.
77. Alquicer G, Silva-Gómez AB, Peralta F, Flores G. Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. Int J Dev Neurosci. 2004;22(2):103-111. doi:10.1016/j.ijdevneu.2003.12.003.
78. Flores G, Barbeau D, Quirion R, Srivastava LK. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci. 1996;16(6):2020-2026.
79. Flores G, Wood GK, Liang JJ, Quirion R, Srivastava LK. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. J Neurosci. 1996;16(22):7366-7375.
80. Schroeder H, Grecksch G, Becker A, Hoellt V, Bogerts B. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Psychopharmacology (Berl). 1999;145:61-66. doi:10.1007/s002130051032.
81. François J, Ferrandon A, Koning E, Angst M-J, Sandner G, Nehlig A. Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats. Int J Neuropsychopharmacol. 2009;12:1097-1110. doi:10.1017/S1461145709009985.
82. Tseng KY, Lewis BL, Hashimoto T, et al. A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. J Neurosci. 2008;28(48):12691-12699. doi:10.1523/JNEUROSCI.4166-08.2008.
83. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 2001;25(01):1-27. doi:10.1016/S0893-133X(01)00 225-1.
84. Flores G, Alquicer G, Silva-Gómez AB, et al. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience. 2005;133:463-470. doi:10.1016/j.neuroscience.2005.02.021.
85. Bringas ME, Morales-Medina JC, Flores-Vivaldo Y, et al. Clozapine administration reverses behavioral, neuronal, and nitric oxide disturbances in the neonatal ventral hippocampus rat. Neuropharmacology. 2012;62(4):1848-1857. doi:10.1016/j.neuropharm.2011.12.008.
86. Hori T, Subramaniam S, Srivastava LK, Quirion R. Behavioral and neurochemical alterations following repeated phencyclidine administration in rats with neonatal ventral hippocampal lesions. Neuropharmacology. 2000;39:2478-2491. doi:10.1016/S0028-3908(00)00059-9.
87. Naert A, Gantois I, Laeremans A, et al. Behavioural alterations relevant to developmental brain disorders in mice with neonatally induced ventral hippocampal lesions. Brain Res Bull. 2013;94:71-81. doi:10.1016/j.brainresbull.2013.01.008.
88. Rueter LE, Ballard ME, Gallagher KB, Basso AM, Curzon P, Kohlhaas KL. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl). 2004;176(3-4): 312-319. doi:10.1007/s00213-004-1897-4.
89. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry. 2003;54(03):1162-1170. doi:10.1016/S0006-3223(03)00374-3.
90. Becker A, Grecksch G. Haloperidol and clozapine affect social behaviour in rats postnatally lesioned in the ventral hippocampus. Pharmacol Biochem Behav. 2003;76(1):1-8. doi:10.1016/S0091-3057(03)00139-4.
91. Le Pen G, Grottick AJ, Higgins GA, Martin JR, Jenck F, Moreau JL. Spatial and associative learning deficits induced by neonatal excitotoxic hippocampal damage in rats: further evaluation of an animal model of schizophrenia. Behav Pharmacol. 2000;11(3-4):257-268.
92. Beninger RJ, Tuerke KJ, Forsyth JK, et al. Neonatal ventral hippocampal lesions in male and female rats: effects on water maze, locomotor activity, plus-maze and prefrontal cortical GABA and glutamate release in adulthood. Behav Brain Res. 2009;202(2):198-209. doi:10.1016/j.bbr.2009.03.044.
93. Lecourtier L, Antal M-C, Cosquer B, et al. Intact neurobehavioral development and dramatic impairments of procedural-like memory following neonatal ventral hippocampal lesion in rats. Neuroscience. 2012;207:110-123. doi:10.1016/j.neuroscience.2012.01.040.
94. Lipska B, Weinberger D. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology. 1994;10(3):199-205.
95. Le Pen G, Moreau JL. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology. 2002;27(1):1-11. doi:10.1016/S0893-133 X(01)00383-9.
96. Levin ED, Christopher NC. Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(2):223-229. doi:10.1016/j.pnpbp.2005.10.018.
97. Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci. 2004;29(4): 282-286.
98. Drouin-Ouellet J, Brownell AL, Saint-Pierre M, et al. Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia. 2011;59(2):188-199.doi:10.1002/glia.21086.
99. Rao JS, Kim H-W, Harry GJ, Rapoport SI, Reese EA. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res. 2013;147(1):24-31. doi:10.1016/j.schres.2013.02.017.
100. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42(2):151-157. doi:10.1016/j.jpsychires.2006.10.013.
101. Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:115-121. doi:10.1016/j.pnpbp.2011.12.002.
102. Zhu F, Zheng Y, Ding Y-Q, et al. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PLoS One. 2014;9(4):e93966. doi:10.1371/journal.pone.0093966.
103. Brown AS. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol. 2012;72:1272-1276. doi:10.1002/dneu.22024.
104. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol. 2010;90(3):285-326. doi:10.1016/j.pneurobio.2009.10.018.
105. Kneeland RE, Fatemi SH. Viral infection, inflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:35-48. doi: 10.1016/j.pnpbp.2012.02.001.
106. Fatemi SH, Folsom TD, Reutiman TJ, et al. Abnormal expression of myelination genes and alterations in white matter fractional anisotropy following prenatal viral influenza infection at E16 in mice. Schizophr Res. 2009;112(1-3):46-53. doi:10.1016/j.schres.2009.04.014.
107. Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry. 2014;75(4):307-315. doi:10.1016/j.biopsych.2013.07.011.
108. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1-14. doi:10.1093/intimm/dxh186.
109. Li Q, Cheung C, Wei R, et al. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One. 2009;4(7):e6354. doi:10.1371/journal.pone.0006354.
110. Piontkewitz Y, Arad M, Weiner I. Abnormal trajectories of neurodevelopment and behavior following in utero insult in the rat. Biol Psychiatry. 2011;70(9):842-851. doi:10.1016/j.biopsych.2011.06.007.
111. Piontkewitz Y, Arad M, Weiner I. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull. 2011;37(6):1257-1269. doi:10.1093/schbul/sbq040.
112. Piontkewitz Y, Assaf Y, Weiner I. Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry. 2009;66(11):1038-1046. doi:10.1016/j.biopsych.2009.07.005.
113. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun. 2008;22(4):469-486. doi:10.1016/j.bbi.2007.09.012.
114. Meyer U, Nyffeler M, Engler A, et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci. 2006;26(18):4752-4762. doi:10.1523/JNEUROSCI.0099-06.2006.
115. Ibi D, Nagai T, Kitahara Y, et al. Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci Res. 2009;64(3):297-305. doi:10.1016/j.neures.2009.03.015.
116. Zuckerman L, Rehavi M, Nachman R, Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology. 2003;28(10):1778-1789. doi:10.1038/sj.npp.1300248.
117. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry. 2006;59(6):546-554. doi:10.1016/j.biopsych.2005. 07.031.
118. Tse MT, Piantadosi PT, Floresco SB. Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research. Biol Psychiatry. 2014:1-11. doi:10.1016/j.biopsych.2014.09.007.
119. Nyffeler M, Meyer U, Yee BK, Feldon J, Knuesel I. Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia. Neuroscience. 2006;143(1):51-62. doi:10.1016/j.neuroscience. 2006.07.029.
120. Richetto J, Calabrese F, Meyer U, Riva MA. Prenatal versus postnatal maternal factors in the development of infection-induced working memory impairments in mice. Brain Behav Immun. 2013;33:190-200. doi:10.1016/j.bbi.2013.07.006.
121. Soumiya H, Fukumitsu H, Furukawa S. Prenatal immune challenge compromises development of upper-layer but not deeper-layer neurons of the mouse cerebral cortex. J Neurosci Res. 2011;89(9):1342-1350. doi:10.1002/jnr.22636.
122. Winter C, Djodari-Irani A, Sohr R, et al. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol. 2009; 12(4):513-524. doi:10.1017/S1461145708009206.
123. Bitanihirwe BK, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology. 2010;35(12):2462-2478. doi:10.1038/npp.2010.129.
124. Roenker NL, Gudelsky G, Ahlbrand R, et al. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett. 2011;500(3):167-171. doi:10.1016/j.neulet.2011.06.011.
125. Holloway T, Moreno JL, Umali A, et al. Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system. J Neurosci. 2013;33(3):1088-1098. doi:10.1523/JNEUROSCI. 2331-12.2013.
126. Dalton VS, Verdurand M, Walker A, Hodgson DM, Zavitsanou K. Synergistic effect between maternal infection and adolescent cannabinoid exposure on serotonin 5HT1A receptor binding in the hippocampus: testing the "two hit" hypothesis for the development of schizophrenia. ISRN Psychiatry. 2012;2012:1-9. doi:10.5402/2012/451865.
127. Selvaraj S, Arnone D, Cappai A, Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014;45:233-245. doi:10.1016/j.neubiorev.2014.06.005.
128. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry. 1998;155(11):1490-1501.
129. Holt DJ, Herman MM, Hyde TM, et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience. 1999;94(1):21-31. doi:10.1016/S0306-4522(99)00279-1.
130. Olincy A, Stevens KE. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol. 2007;74(8):1192-1201. doi:10.1016/j.bcp.2007.07.015.
131. Berman JA, Talmage DA, Role LW. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol. 2007;78:193-223. doi:10.1016/S0074-7742(06)78007-2.
132. Money TT, Scarr E, Udawela M, et al. Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol Disord Drug Targets. 2010;9(2):241-256.
133. Wu W-L, Adams CE, Stevens KE, Chow K-H, Freedman R, Patterson PH. The interaction between maternal immune activation and alpha 7 nicotinic acetylcholine receptor in regulating behaviors in the offspring. Brain Behav Immun. 2015;46:192-202.
134. Li W-Y, Chang Y-C, Lee LJ, Lee L-J. Prenatal infection affects the neuronal architecture and cognitive function in adult mice. Dev Neurosci. 2014;36(5):359-370. doi:10.1159/000362383.
135. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90-107. doi:10.1016/j.neuroscience. 2012.04.044.
136. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015; 161(1):102-112. doi:10.1016/j.schres.2014.04.041.
137. Hagmann P, Jonasson L, Maeder P, Thiran J-P, Wedeen VJ, Meuli R. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics. 2006;26(Suppl 1):S205-S223. doi:10.1148/rg.26si065510.
138. Alvarado-Alanis P, Leon-Ortiz P, Reyes-Madrigal F, et al. Abnormal white matter integrity in antipsychotic-naive first-episode psychosis patients assessed by a DTI principal component analysis. Schizophr Res. 2015;162(1-3):14-21. doi:10.1016/j.schres.2015.01.019.
139. Li Q, Cheung C, Wei R, et al. Voxel-based analysis of postnatal white matter microstructure in mice exposed to immune challenge in early or late pregnancy. Neuroimage. 2010;52(1):1-8. doi:10.1016/j.neuroimage.2010.04.015.
140. Dickerson DD, Bilkey DK. Aberrant neural synchrony in the maternal immune activation model: using translatable measures to explore targeted interventions. Front Behav Neurosci. 2013;7(12):217. doi:10.3389/fnbeh.2013.00217.
141. Dickerson DD, Overeem KA, Wolff AR, Williams JM, Abraham WC, Bilkey DK. Association of aberrant neural synchrony and altered GAD67 expression following exposure to maternal immune activation, a risk factor for schizophrenia. Transl Psychiatry. 2014;4(7):e418. doi:10.1038/tp.2014.64.
142. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27(40):10695-10702. doi:10.1523/JNEUROSCI.2178-07.2007.
143. Khan D, Fernando P, Cicvaric A, et al. Long-term effects of maternal immune activation on depression-like behavior in the mouse. Transl Psychiatry. 2014;4:e363. doi:10.1038/tp.2013.132.
144. Zhang Z, van Praag H. Maternal immune activation differentially impacts mature and adult-born hippocampal neurons in male mice. Brain Behav Immun. 2015;45:60-70. doi:10.1016/j.bbi.2014.10.010.
145. Zhang Y, Cazakoff BN, Thai CA, Howland JG. Prenatal exposure to a viral mimetic alters behavioural flexibility in male, but not female, rats. Neuropharmacology. 2012;62(3):1299-1307. doi:10.1016/j.neuropharm.2011.02.022.
146. Howland JG, Cazakoff BN, Zhang Y. Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neuroscience. 2012;201:184-198. doi:10.1016/j.neuroscience.2011. 11.011.
147. Khan D, Fernando P, Cicvaric A, et al. Long-term effects of maternal immune activation on depression-like behavior in the mouse. Transl Psychiatry. 2014;4:e363. doi:10.1038/tp.2013.132.
148. Meyer U, Knuesel I, Nyffeler M, Feldon J. Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacology (Berl). 2010;208(4):531-543. doi:10.1007/s00213-009-1754-6.
149. Missault S, Van den Eynde K, Vanden Berghe W, et al. The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model. Brain Behav Immun. 2014;42:138-146. doi:10.1016/j.bbi.2014.06.013.
150. Arrode-Brusés G, Brusés JL. Maternal immune activation by poly I:C induces expression of cytokines IL-1β and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. J Neuroinflammation. 2012;9(1):83. doi:10.1186/1742-2094-9-83.
151. Pratt L, Ni L, Ponzio NM, Jonakait GM. Maternal inflammation promotes fetal microglial activation and increased cholinergic expression in the fetal basal forebrain: role of interleukin-6. Pediatr Res. 2013;74(4):393-401. doi:10.1038/pr.2013.126.
152. Ratnayake U, Quinn T, LaRosa DA, Dickinson H, Walker DW. Prenatal exposure to the viral mimetic poly I:C alters fetal brain cytokine expression and postnatal behaviour. Dev Neurosci. 2014;36(2):83-94. doi:10.1159/000362205.
153. Jack CS, Arbour N, Manusow J, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol. 2005;175(7):4320-4330.
154. Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron. 2013;77(1):10-18. doi:10.1016/j.neuron.2012.12.023.
155. Cunningham CL, Martínez-Cerdeño V, Noctor SC. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J Neurosci. 2013;33(10):4216-4233. doi:10.1523/JNEUROSCI.3441-12.2013.
156. Garay PA, Hsiao EY, Patterson PH, Mcallister AK. Maternal immune activation causes age-and region-specific changes in brain cytokines in offspring throughout development. Brain Behav Immun. 2013;31:54-68. doi:10.1016/j.bbi.2012.07.008.
157. Van den Eynde K, Missault S, Fransen E, et al. Hypolocomotive behaviour associated with increased microglia in a prenatal immune activation model with relevance to schizophrenia. Behav Brain Res. 2014;258:179-186. doi:10.1016/j.bbr.2013.10.005.
158. Zhu F, Zheng Y, Liu Y, Zhang X, Zhao J. Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic-polyribocytidilic acid. Psychiatry Res. 2014;219(3):680-686. doi:10.1016/j.psychres.2014.06.046.
159. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol. 2013;27(4):337-342. doi:10.1177/0269881112467089.
160. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40(1):181-191. doi:10.1093/schbul/sbt139.
161. Patterson PH. Modeling autistic features in animals. Pediatr Res. 2011;69(5):34-40. doi:10.1203/PDR.0b013e318212b80f.
162. Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med. 2011;17(7):389-394. doi:10.1016/j.molmed.2011. 03.001.
163. Suzuki K, Sugihara G, Ouchi Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry. 2013;70:49-58. doi:10.1001/jamapsychiatry.2013.272.
164. Rodriguez JI, Kern JK. Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biol. 2012;7:1-9. doi:10.1017/S1740925X12000142.
165. Theoharides TC, Athanassiou M, Panagiotidou S, Doyle R. Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders. J Neuroimmunol. 2015;279:33-38. doi:10.1016/j.jneuroim.2014.12.003.
166. Baharnoori M, Bhardwaj SK, Srivastava LK. Effect of maternal lipopolysaccharide administration on the development of dopaminergic receptors and transporter in the rat offspring. PLoS One. 2013;8(1):18-23. doi:10.1371/journal.pone.0054439.
167. Santana N, Mengod G, Artigas F. Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex. 2009;19(4): 849-860. doi:10.1093/cercor/bhn134.
168. Borrell J, Vela JM, Arévalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats: implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology. 2002;26(2):204-215. doi:10.1016/S0893-133X(01)00360-8.
169. Romero E, Ali C, Molina-Holgado E, Castellano B, Guaza C, Borrell J. Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology. 2007;32(8):1791-1804. doi:10.1038/sj.npp.1301292.
170. Baharnoori M, Brake WG, Srivastava LK. Prenatal immune challenge induces developmental changes in the morphology of pyramidal neurons of the prefrontal cortex and hippocampus in rats. Schizophr Res. 2009;107(1):99-109. doi:10.1016/j.schres.2008.10.003.
171. Golan HM, Lev V, Hallak M, Sorokin Y, Huleihel M. Specific neurodevelopmental damage in mice offspring following maternal inflammation during pregnancy. Neuropharmacology. 2005;48(6):903-917. doi:10.1016/j.neuropharm.2004.12.023.
172. Basta-Kaim A, Fijal K, Slusarczyk J, et al. Prenatal administration of lipopolysaccharide induces sex-dependent changes in glutamic acid decarboxylase and parvalbumin in the adult rat brain. Neuroscience. 2015;287:78-92. doi:10.1016/j.neuroscience.2014.12.013.
173. Wischhof L, Irrsack E, Osorio C, Koch M. Prenatal LPS-exposure-a neurodevelopmental rat model of schizophrenia-differentially affects cognitive functions, myelination and parvalbumin expression in male and female offspring. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:17-30. doi:10.1016/j.pnpbp.2014.10.004.
174. Lin Y-L, Wang S. Prenatal lipopolysaccharide exposure increases depression-like behaviors and reduces hippocampal neurogenesis in adult rats. Behav Brain Res. 2014;259:24-34. doi:10.1016/j.bbr.2013.10.034.
175. Kirsten TB, Taricano M, Maiorka PC, Palermo-Neto J, Bernardi MM. Prenatal lipopolysaccharide reduces social behavior in male offspring. Neuroimmunomodulation. 2010;17(4):240-251. doi:10.1159/000290040.
176. Foley KA, MacFabe DF, Vaz A, Ossenkopp K-P, Kavaliers M. Sexually dimorphic effects of prenatal exposure to propionic acid and lipopolysaccharide on social behavior in neonatal, adolescent, and adult rats: implications for autism spectrum disorders. Int J Dev Neurosci. 2014;39:68-78. doi:10.1016/j.ijdevneu.2014.04.001.
177. Hava G, Vered L, Yael M, Mordechai H, Mahoud H. Alterations in behavior in adult offspring mice following maternal inflammation during pregnancy. Dev Psychobiol. 2006;48(2):162-168. doi:10.1002/dev.20116.
178. Chlodzinska N, Gajerska M, Bartkowska K, Turlejski K, Djavadian RL. Lipopolysaccharide injected to pregnant mice affects behavior of their offspring in adulthood. Acta Neurobiol Exp (Wars). 2011;71(4):519-527.
179. Basta-Kaim A, Budziszewska B, Leskiewicz M, et al. Hyperactivity of the hypothalamus-pituitary-adrenal axis in lipopolysaccharide-induced neurodevelopmental model of schizophrenia in rats: effects of antipsychotic drugs. Eur J Pharmacol. 2011;650(2-3):586-595. doi:10.1016/j.ejphar.2010.09.083.
180. Lin Y-L, Lin S-Y, Wang S. Prenatal lipopolysaccharide exposure increases anxiety-like behaviors and enhances stress-induced corticosterone responses in adult rats. Brain Behav Immun. 2012;26(3): 459-468. doi:10.1016/j.bbi.2011.12.003.
181. Basta-kaim A, Szczêsny E, Leoekiewicz M, et al. Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring-the effect of antipsychotic drugs. Pharmacol Rep. 2012;64(6):1400-1410.
182. Graciarena M, Depino AM, Pitossi FJ. Prenatal inflammation impairs adult neurogenesis and memory related behavior through persistent hippocampal TGFbeta1 downregulation. Brain Behav Immun. 2010; 24(8):1301-1309. doi:10.1016/j.bbi.2010.06.005.
183. Graciarena M, Roca V, Mathieu P, Depino AM, Pitossi FJ. Differential vulnerability of adult neurogenesis by adult and prenatal inflammation: role of TGF-beta1. Brain Behav Immun. 2013;34:17-28. doi:10.1016/j.bbi.2013.05.007.
184. Battista D, Ferrari CC, Gage FH, Pitossi FJ. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci. 2006;23(1):83-93. doi:10.1111/j.1460-9568.2005.04539.x.
185. Sierra A, Encinas JM, Deudero JJ, et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell. 2010;7(4):483-495. doi:10.1016/j.stem.2010.08.014.
186. Ibi D, Nagai T, Kitahara Y, et al. Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci Res. 2009;64(3):297-305. doi:10.1016/j.neures.2009.03.015.
187. Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res. 2001;47:27-36. doi:10.1016/S0920-9964(00)00032-3.
188. Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry. 2006;11:47-55. doi:10.1038/sj.mp.4001748.
189. Maynard TM, Sikich L, Lieberman JA, LaMantia AS. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr Bull. 2001;27:457-476.
190. Lipina TV, Zai C, Hlousek D, Roder JC, Wong AH. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. J Neurosci. 2013;33(18):7654-7666. doi:10.1523/JNEUROSCI.0091-13.2013.
191. Giovanoli S, Weber L, Meyer U. Single and combined effects of prenatal immune activation and peripubertal stress on parvalbumin and reelin expression in the hippocampal formation. Brain Behav Immun. 2014;40:48-54.
192. Giovanoli S, Engler H, Engler A, et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science. 2013;339(6123):1095-1099.
193. Deslauriers J, Larouche A, Sarret P, Grignon S. Combination of prenatal immune challenge and restraint stress affects prepulse inhibition and dopaminergic/GABAergic markers. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:156-164.